Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07144254 · ClinicalTrials.gov registry record · Phase 1
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
A Phase 1 study of Refractory Osteosarcoma and Osteosarcoma Recurrent, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07144254 is a Phase 1 study of Refractory Osteosarcoma and Osteosarcoma Recurrent that is actively recruiting participants, run by Emory University. The registered enrollment target is 24 participants, below the 34-participant average among 7 other Refractory Osteosarcoma trials with a reported enrollment target (29% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07144254, a Phase 1 study of Refractory Osteosarcoma and Osteosarcoma Recurrent, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to define the maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D) of Tegavivint in combination with Gemcitabine in patients with relapsed or refractory osteosarcoma (OS). The study will also investigate the toxicities of Tegavivint in combination with gemcitabine in patients with relapsed or refractory OS.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Tegavivint
Study Locations (1)
Georgia
- Arthur M. Blank Children's Healthcare of Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-01-22 |
| Est. Completion | 2028-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07144254
The ClinicalTrials.gov registry entry for NCT07144254 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 34-participant average among 7 other Refractory Osteosarcoma trials with a reported enrollment target (29% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Refractory Osteosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Gemcitabine is the first listed.
NCT07144254 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT07144254 about?
NCT07144254 is a clinical study titled "Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma". The goal of this clinical trial is to define the maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D) of Tegavivint in combination with Gemcitabine in patients with relapsed or refractory osteosarcoma (OS). The study will also investigate the toxicities of Tegavivint in combination w...
What is the current status of trial NCT07144254?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-01-22. Estimated completion is 2028-05.
What conditions does trial NCT07144254 study?
This clinical trial studies the following conditions: Refractory Osteosarcoma, Osteosarcoma Recurrent, Osteosarcoma in Children, Relapsed Osteosarcoma.
What interventions are being tested in trial NCT07144254?
The interventions under investigation include: Gemcitabine (DRUG), Tegavivint (DRUG).
Who is sponsoring clinical trial NCT07144254?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07144254 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial
RECRUITING · Phase 1
-
Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma
RECRUITING · Phase 1
-
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma
ACTIVE NOT RECRUITING · Phase 1
-
Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors
COMPLETED · Phase 1
-
Cabozantinib With Topotecan-Cyclophosphamide
COMPLETED · Phase 1
-
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.